Margaret T Kasner MD MSCE

Oncology•Philadelphia, PA

Hematologic Oncology

Professor of Medical Oncology, Thomas Jefferson University

Join to View Full Profile

1101 Chestnut Street14th FlPhiladelphia, PA 19103
Phone+1 215-955-8874
Fax+1 215-955-2010

Summary

Dr. Margaret Kasner is an oncologist based in Philadelphia, PA, specializing in hematologic oncology with a focus on conditions such as acute myeloid leukemia, lymphoid leukemia, and related disorders. She completed her fellowship in Hematology and Medical Oncology and residency in Internal Medicine at the University of Pennsylvania Health System, after graduating from the Perelman School of Medicine. Dr. Kasner is an accomplished researcher with publications on leukemia treatment strategies and has been involved in various clinical trials addressing both leukemia and myelodysplastic syndrome. She is the current medical director of the Sidney Kimmel Comprehensive Cancer Center Clinical Trials Operations and the incoming Associate Director of Clinical Research.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Pennsylvania Health SystemResidency, Internal Medicine, 2001 - 2004
Perelman School of Medicine at the University of PennsylvaniaClass of 2001

Certifications & Licensure

DE State Medical License 2018 - 2027
PA State Medical License 2001 - 2026
NJ State Medical License 2017 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2012

Clinical Trials

Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
Completed
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma Start of enrollment: 2009 Feb 05
Completed
Phase 2
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy Start of enrollment: 2010 Jul 01
Completed
Early Phase 1
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 Jul 01
Completed
Not Applicable
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies Start of enrollment: 2008 Apr 10
Completed
Phase 2
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors Start of enrollment: 2011 Feb 10
Completed
Phase 2
Treatment of Sickle Cell Anemia With Stem Cell Transplant Start of enrollment: 2009 Sep 01
Terminated
Not Applicable
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma Start of enrollment: 2011 May 25
Terminated
Phase 1
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Start of enrollment: 2011 Aug 04
Completed
Phase 2
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide Start of enrollment: 2011 Nov 09
Completed
Phase 1, Phase 2
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant Start of enrollment: 2012 Aug 01
Withdrawn
Not Applicable
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Start of enrollment: 2012 Dec 24
Completed
Phase 2
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Mar 15
Completed
Early Phase 1
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08
Active, not recruiting
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor Start of enrollment: 2013 Nov 04
Completed
Phase 2
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2014 Aug 25
Completed
Phase 2
STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy Start of enrollment: 2017 Mar 17
Completed
Phase 1
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Start of enrollment: 2018 May 09
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Targeting CD47: many misses; hopeful for a hit.
Lindsay Wilde, Margaret Kasner
Blood. 2025-01-30
North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era.
Margaret Kasner, Angela H Fritsche, Man Chong Leong, Kendra Cameron, Carrie B Lee
JCO Oncology Practice. 2024-12-01
1 citations
Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions.
Omer Hassan Jamy, Margaret Kasner, Sarah Wall, Stacey Ingram, D 'Ambra Dent
Leukemia Research. 2023-11-01

Abstracts/Posters

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
Margaret Kasner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

A phase I trial of palbociclib in combination with dexamethasone in relapsed or refractory adult B-cell acute lymphoblastic leukemia (ALL).
2019 ASCO Annual Meeting - 6/1/2019